Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics, Inc. (VERA) reports that President and CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock on September 15, 2026 at an exercise price of $2.8968 per share, then sold 18,500 shares at $37.00 per share under a Rule 10b5-1 trading plan. Following the option exercise, he held 488,801 options directly.
Vera Therapeutics, Inc. (VERA) reported final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy at risk for disease progression. In 428 treated patients, TRUTAKNA stabilized kidney function versus placebo and met all prespecified endpoints.
At 52 weeks, mean eGFR change was -0.1 mL/min/1.73m² with TRUTAKNA compared with -5.7 with placebo, a placebo‑adjusted difference of 5.6 mL/min/1.73m²; the annualized eGFR slope through 104 weeks showed a 5.0 mL/min/1.73m² per year placebo‑adjusted benefit. The composite kidney disease progression endpoint showed a 76% risk reduction with a hazard ratio of 0.24.
TRUTAKNA also achieved statistically significant improvements in proteinuria, galactose‑deficient IgA1, and hematuria. The safety profile was generally comparable to placebo, with similar overall infection rates and no opportunistic infections or clinically relevant hypogammaglobulinemia reported. Vera states it plans to submit a supplemental BLA in the fourth quarter of 2026, targeting potential full approval in 2027.
Vera Therapeutics, Inc. (VERA) reported that Joseph R. Young, SVP, Finance and Chief Accounting Officer, exercised stock options for 5,000 shares of Class A common stock on September 11, 2026 at an exercise price of $3.9396 per share. The exercise reduced the derivative position tied to this option by 5,000 shares and increased his directly held common stock to 80,754 shares, while he continues to hold 33,589 stock options following the transaction. The option began vesting on March 9, 2022, with monthly vesting thereafter, and no Rule 10b5-1 trading plan is reported for these transactions.
Vera Therapeutics, Inc. reported that its president and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A common stock on September 2, 2026 at an exercise price of $2.8968 per share and received the same number of shares. On the same date, he sold 18,500 shares at a weighted-average price of $35.1158 per share under a Rule 10b5-1 trading plan adopted on January 9, 2026. Following the option exercise, he held 507,301 shares subject to the exercised option grant.
Vera Therapeutics, Inc. (VERA) received a notice that stockholder Marshall Fordyce intends to sell up to 64,750 shares of common stock under Rule 144. The shares will be delivered from the exercise of stock options for cash through Morgan Stanley Smith Barney, with sales noted as of September 2, 2026 on NASDAQ.
The notice also lists prior Rule 10b5-1 plan sales of Vera Therapeutics common stock by Marshall Fordyce over the past three months.
Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of Vera Therapeutics, Inc. Class A common stock. They have shared voting and dispositive power over 2,890,059 shares, representing 4.01% of the class, and state ownership of 5 percent or less of the class.
Vera Therapeutics, Inc. president and CEO Marshall Fordyce exercised stock options covering 46,250 shares of Class A Common Stock on July 7, 2026 at an exercise price of $2.8968 per share, and on the same date sold 46,250 shares in multiple transactions at weighted-average prices between $40.7762 and $43.5947. The option, which vests over four years and expires on December 15, 2030, showed 525,801 derivative securities beneficially owned following the reported exercise. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on January 9, 2026.
Vera Therapeutics, Inc. President and CEO Marshall Fordyce reported option exercises and share sales in Class A Common Stock. On June 23, 2026, he exercised options for 18,500 shares at an exercise price of $2.8968 per share, increasing directly held common stock by the same amount. The related option position showed 572,051 derivative shares beneficially owned after the exercise. On the same date, he sold 18,412 shares at a weighted-average price of $37.9311 and an additional 88 shares at $38.43 per share. The sales were made pursuant to a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements.
Vera Therapeutics, Inc. reported that President and CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock on May 12, 2026 at an exercise price of $2.8968 per share. The option exercise left 590,551 stock options outstanding under this award. On the same date, he sold 18,500 shares of Class A Common Stock in open-market transactions, including 14,219 shares at a weighted-average price of $36.6396 and 4,281 shares at a weighted-average price of $37.0868. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026.
Vera Therapeutics, Inc. reported a larger net loss as it ramps up commercialization of its first FDA‑approved product, TRUTAKNA, for IgA nephropathy. For the six months ended June 30, 2026, the company recorded a net loss of $230.5 million, compared with $128.2 million a year earlier, driven by higher research and development and sharply higher general and administrative spending.
Total operating expenses rose to $237.6 million from $137.3 million, including $146.1 million in research and development and $91.5 million in general and administrative costs, reflecting increased headcount, stock‑based compensation, clinical trials, drug manufacturing, and commercial launch preparation. Cash, cash equivalents and marketable securities were $499.2 million as of June 30, 2026, down from $714.6 million at year‑end, after $206.8 million of operating cash outflows in the first half. Long‑term debt outstanding under the 2025 loan agreement was $75.0 million.
On July 7, 2026, after the quarter end, the FDA granted accelerated approval to TRUTAKNA based on Phase 3 data showing a 46% proteinuria reduction from baseline and a 42% reduction versus placebo at 36 weeks, and Vera expects only limited product revenue to begin in the third quarter of 2026.